Clostridium News and Research

RSS

Prevention training critical to reduction of hospital infection rates

Infections picked up in hospital affect almost a third of patients in intensive care, and kill 44% of those people. Given that some infectious agents can linger for weeks or months it is increasingly important that staff awareness of the problem is improved and that training in infection prevention across the National Health Service and in private healthcare is expanded, according to researchers at the University of Northampton.

15 Oct 2011

Four companies receive NIAID contracts to develop broad-spectrum therapeutics

Four companies are to develop broad-spectrum therapeutics-antibiotics, antivirals and an antitoxin-to prevent or treat diseases caused by multiple types of bacteria or viruses, under contracts awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

14 Oct 2011

Thomson Reuters launches Infection Xpert solution

Thomson Reuters, a global provider of information for healthcare professionals, has launched Infection Xpert — a clinical intelligence dashboard that helps infection preventionists (IPs) manage and reduce hospital-acquired infections (HAIs), capture and submit mandated infection reporting metrics, and analyze hospital infection data to improve patient safety.

12 Oct 2011

Virginia Bioinformatics Institute releases upgraded ENISI software

Researchers with the Virginia Bioinformatics Institute at Virginia Tech have released an upgrade to the institute's ENteric Immunity SImulator (ENISI) software, which models immune responses to beneficial and harmful bacteria that enter the gastrointestinal tract of mice, pigs, and humans.

7 Oct 2011

Cubist plans to move CB-183,315 into Phase 3 trial for treatment of CDAD

Cubist Pharmaceuticals, Inc. today announced it plans to move CB-183,315, being studied for the treatment of a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea, or CDAD, into late-stage trials.

29 Sep 2011

Researchers discover cell receptor for CDT toxin of C. difficile bacterium

A research group led by Freiburg pharmacologist Prof. Dr. Klaus Aktories and their American colleagues have discovered the cell receptor for the toxin CDT of the bacterium Clostridium difficile.

27 Sep 2011

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhea.

26 Sep 2011

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

Astellas Pharma Europe Ltd. (APEL) and Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhoea (CDAD).

23 Sep 2011

Powerful new antibiotic treatment for MRSA and C. difficile bugs

MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde in Glasgow, Scotland, is developing a powerful new antibiotic treatment for resistant infections including the deadly MRSA and Clostridium difficile (C. diff.) bugs.

20 Sep 2011

Auxilium reports positive data from XIAFLEX retrospective commercial patient chart review

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that positive data from a retrospective commercial patient chart review of XIAFLEX (collagenase clostridium histolyticum) used for the treatment of adult Dupuytren's contracture patients with a palpable cord are available via e-posters at the American Society for Surgery of the Hand meeting in Las Vegas.

8 Sep 2011

Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from a pilot clinical study to assess safety, tolerability, and multiple-dose pharmacokinetics of XIAFLEX (collagenase clostridium histolyticum) in adult Dupuytren's contracture subjects with multiple palpable cords.

7 Sep 2011

C. sporogenes bacterium could be used as vehicle to deliver drugs in frontline cancer therapy

A bacterial strain that specifically targets tumours could soon be used as a vehicle to deliver drugs in frontline cancer therapy. The strain is expected to be tested in cancer patients in 2013 says a scientist at the Society for General Microbiology's Autumn Conference at the University of York.

5 Sep 2011

Insight into how bacterial toxins cause human diseases may help improve treatment

A better understanding of how bacterial toxins cause common human diseases may lead to their improved treatment and prevention according to a paper just published by Irish and US scientists in Nature Reviews Microbiology.

25 Aug 2011

Cone Health uses Xenex room disinfection systems to reduce HAI rates and costs

Cone Health today announced a dramatic reduction in healthcare-acquired infection (HAIs) rates after implementing an infection prevention program which includes Xenex room disinfection systems.

25 Aug 2011

Hospital acquired Clostridium difficile bug defense system identified

American researchers have discovered the process by which the cells in the gut fight off toxins produced by a hospital bug - Clostridium difficile. Writing in Nature Medicine, they showed how a chemical - GSNO - deactivated a toxin from Clostridium difficile which causes inflammation and diarrhea. They hope to use their findings to develop a treatment for C. difficile.

23 Aug 2011

Research uncovers natural defense mechanism that inactivates C. diff toxins

Groundbreaking research encompassing Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, has uncovered a natural defense mechanism that is capable of inactivating the toxin that spreads Clostridium difficile, or C. diff, an increasingly common bacterial infection in hospitals and long-term care settings.

22 Aug 2011

Scientists discover key defense mechanism against C. difficile infection

Researchers have discovered a key mechanism used by intestinal cells to defend themselves against one of the world's most common hospital-acquired bacterial infections - a mechanism they think they can exploit to produce a therapy to protect against the effects of the antibiotic-resistant bacteria.

22 Aug 2011

New CDI therapeutic approach may offer treatment for other bacterial diseases

Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.

22 Aug 2011

C. difficile infection more prevalent in Chicago-area acute care hospitals

An outbreak strain of Clostridium difficile, a bacterium that causes diarrhea and sometimes life-threatening inflammation of the colon, is common in Chicago-area acute care hospitals, an investigation published in the September issue of Infection Control and Hospital Epidemiology suggests.

12 Aug 2011

UTHealth student receives UNCF/Merck fellowship for multidrug-resistant CDI research

Charles Darkoh, a graduate student at The University of Texas Health Science Center at Houston (UTHealth), has been awarded a fellowship from the United Negro College Fund (UNCF) and Merck for his research into a major health problem - multidrug-resistant Clostridium difficile bacterial infection.

3 Aug 2011

Clostridium News and Research

Prevention training critical to reduction of hospital infection rates

Four companies receive NIAID contracts to develop broad-spectrum therapeutics

Thomson Reuters launches Infection Xpert solution

Virginia Bioinformatics Institute releases upgraded ENISI software

Cubist plans to move CB-183,315 into Phase 3 trial for treatment of CDAD

Researchers discover cell receptor for CDT toxin of C. difficile bacterium

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

Powerful new antibiotic treatment for MRSA and C. difficile bugs

Auxilium reports positive data from XIAFLEX retrospective commercial patient chart review

Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects

C. sporogenes bacterium could be used as vehicle to deliver drugs in frontline cancer therapy

Insight into how bacterial toxins cause human diseases may help improve treatment

Cone Health uses Xenex room disinfection systems to reduce HAI rates and costs

Hospital acquired Clostridium difficile bug defense system identified

Research uncovers natural defense mechanism that inactivates C. diff toxins

Scientists discover key defense mechanism against C. difficile infection

New CDI therapeutic approach may offer treatment for other bacterial diseases

C. difficile infection more prevalent in Chicago-area acute care hospitals

UTHealth student receives UNCF/Merck fellowship for multidrug-resistant CDI research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News